Showing results (51-60 of 90) with videos related to
Sort By:
Pageof 9
International Journal of Molecular Sciences|January 21, 2022
Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future PerspectivesDavide Ciardiello, Brigida Anna Maiorano, Paola Parente, et al.Cancers|November 27, 2021
Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge StrategyDavide Ciardiello, Vincenzo Famiglietti, Stefania Napolitano, et al.Healthcare (Basel, Switzerland)|April 23, 2022
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case SeriesLuigi Pio Guerrera, Gabriella Suarato, Rossella Napolitano, et al.Cancers|January 8, 2025
Real-World Data of Patients with BRAF V600E-Mutated Metastatic Colorectal Cancer Treated with Trifluridine/TipiracilJavier Ros, Jose Maria Ucha, Eduardo Garcia-Galea, et al.The Oncologist|May 23, 2022
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the COVID-19 PandemicStefania Napolitano, Vincenza Caputo, Anna Ventriglia, et al.International Journal of Cardiology|September 6, 2023
Comparison of different treatment strategies in patients with chronic thromboembolic pulmonary hypertension: a single centre real-world experienceFabio Dardi, Mariangela Rotunno, Daniele Guarino, et al.Journal of Experimental & Clinical Cancer Research : CR|January 30, 2019
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell linesPietro Paolo Vitiello, Claudia Cardone, Giulia Martini, et al.Cancers|April 13, 2023
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical TrialsDavide Ciardiello, Stefania Napolitano, Vincenzo Famiglietti, et al.ESMO Open|October 12, 2017
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programmeVincenzo Sforza, Erika Martinelli, Claudia Cardone, et al.Ageing Research Reviews|June 1, 2025
"Aging and epigenetic implications in radiotherapy: The promise of BNCT"Chiara Papulino, Marco Crepaldi, Gregorio Favale, et al.Pageof 9